For the first time, clinicians have pharmacologic tools that produce durable, clinically meaningful weight loss in a field where most older options were modest, short-lived, or poorly tolerated
Whats Next Inclusion on the DDC lists would limit Ozempic and Mounjaro (marketed for type 2 diabetes) and Wegovy and Zepbound (marketed for chronic weight management) from being compounded by pharmacists, physicians, and outsourcing facilities, even during any current or future shortages of these products
The most read Vaginal Microbiota: What It Is and How to Keep It Healthy 7 January, 2025Explore the vaginal microbiota and its function
BHRC BLOG AOD-9604 Safety Profile: What Clinical Trials Show AOD-9604 Safety Profile: What Clinical Trials Show When considering any peptide therapy, understanding its safety profile is paramount
Retatrutide is developed by Eli Lilly and Company, the same company that makes tirzepatide (Zepbound and Mounjaro)
The authors would like to thank Brenner Thornton for valuable discussions